rifalazil

Infectious disease A rifampin derivative effective against TB, which has a longer T_1⁄2 and intracellular concentrations, allowing shorter treatment, fewer doses, better Pt compliance. See Rifampin.

Mentioned in ?

rifampin

References in periodicals archive ?

Rifalazil treats and prevents relapse of Clostridium difficile-associated diarrhea in hamsters.

Standardization of a model of Clostridium difficile infection in syrian hamsters Mesocricetus auratus/Padronizacao de um modelo de infeccao por Clostridium difficile em hamsters sirios Mesocricetus auratus

An antibiotic called Rifalazil (ActivBiotics Inc.) is in phase II development, along with a monoclonal antibody to toxin A and B (Medarex Inc.).

Consider newer therapies to treat new strain of C. difficile

Among other programs, ActivBiotics is developing Rifalazil, a potent broad-spectrum antibiotic that targets and inhibits the transcriptional machinery of bacteria.

ActivBiotics announces patent issuances covering bacterial infection treatments

(Lexington, MA) announced that the United States Patent and Trademark Office recently issued several patents that expand the coverage of the company's lead compound rifalazil. United States Patent 6,316,433; 6,566,354 and 6,362,169 cover certain dosage regimens and formulations that are believed to be of great clinical importance in treating bacterial infections.

ActivBiotics exclusively licensed rifalazil from Kaneka Corporation (Japan).

We hope to carry rifalazil through the remaining clinical trials for registration within two years, which should enable the drug to be available on the formulary very soon thereafter.

Bernard Cabana, ActivBiotics' VP of Preclinical and Clinical Pharmacology and former founder and Director of the FDA's Division of Biopharmaceutics, stated, "The pharmacokinetic and tissue distribution of rifalazil is best described by a two-compartment open-model.

Chalom Sayada, M.D., Ph.D., ActivBiotics' CEO stated, "These patents reflect our new understanding of the unique potency, distribution, and pharmacokinetic properties of our lead compound, and should allow us to develop rifalazil for a broad number of indications in the near future.